Datapharm joins the Sustainable Medicines Partnership
YewMaker, the executive lead of the Sustainable Medicines Partnership (SMP), is announcing that Datapharm (WPO) has joined as a founding Collaborator.
The SMP is a not-for-profit private-public collaboration executing projects to make the use of medicines more sustainable and less wasteful.
Datapharm is a healthcare solutions company, providing technology-enabled products to the global life sciences industry. Its core product, emc, is a website which contains regulated medicines safety information for patients and healthcare professionals.
In its collaboration with the SMP, Datapharm will support the Digitising Medicines Information Project, offering its unique insight into the industry’s adoption of electronic patient information leaflets, challenges around document conversion, and the possibilities offered by digital solutions for the management and distribution of medicines information.
Posted 29/03/22
-End
Contacts:
YewMaker: comms@yewmaker.com
YewMaker: servicedesk@datapharm.com
About the Sustainable Medicines Partnership
The SMP is a not-for-profit, private-public, multi-stakeholder collaboration. Through executing priority actions, the Sustainable Medicines Partnership aims to stop the avoidable waste of medicines and medicines packaging - reducing healthcare emissions and increasing health equity globally. Learn more at www.yewmaker.com/smp
About YewMaker
YewMaker builds science-based, scalable concepts and solutions that make healthcare more sustainable. YewMaker is the initiator and executive lead of the Sustainable Medicines Partnership. Learn more at www.yewmaker.com
About Datapharm
Datapharm is a medicine information company that provides technology-enabled regulatory, compliance and commercial software solutions to the global life sciences and wider healthcare sectors. Its leading platforms improve the accessibility and usability of medicine information, enabling the delivery of trusted and accessible medical information to all healthcare professionals and patients. For more information, please visit https://www.datapharm.com/